These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37470920)

  • 1. Probing the origins of programmed death ligand-1 inhibition by implementing machine learning-assisted sequential virtual screening techniques.
    Kuttappan S; Bhowmik R; Gopi Mohan C
    Mol Divers; 2023 Jul; ():. PubMed ID: 37470920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
    Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation.
    DiFrancesco M; Hofer J; Aradhya A; Rufinus J; Stoddart J; Finocchiaro S; Mani J; Tevis S; Visconti M; Walawender G; DiFlumeri J; Fattakhova E; Patil SP
    Comput Biol Chem; 2023 Feb; 102():107804. PubMed ID: 36610303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations.
    Mejías C; Guirola O
    J Mol Graph Model; 2019 Sep; 91():105-111. PubMed ID: 31202914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation.
    Choorakottayil Pushkaran A; K K; T AM; Biswas R; Mohan CG
    Mol Inform; 2023 Jun; 42(6):e2200254. PubMed ID: 36897739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
    Mittal L; Tonk RK; Awasthi A; Asthana S
    Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
    Luo L; Zhong A; Wang Q; Zheng T
    Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.
    Urban VA; Davidovskii AI; Veresov VG
    J Biomol Struct Dyn; 2023 Jul; 41(11):5345-5361. PubMed ID: 35696453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents.
    Kamal MA; Badary HA; Omran D; Shousha HI; Abdelaziz AO; El Tayebi HM; Mandour YM
    ACS Omega; 2023 Sep; 8(37):33242-33254. PubMed ID: 37744828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance.
    Wang Y; Guo H; Feng Z; Wang S; Wang Y; He Q; Li G; Lin W; Xie XQ; Lin Z
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31640203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1.
    Ahmed M; Ganesan A; Barakat K
    BMC Chem; 2022 Jun; 16(1):49. PubMed ID: 35761353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
    Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
    Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
    Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
    Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
    Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer.
    Bazzazi H; Shahraz A
    J Theor Biol; 2021 Aug; 522():110697. PubMed ID: 33794288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
    Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
    Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy.
    Kumar GS; Moustafa M; Sahoo AK; Malý P; Bharadwaj S
    Life (Basel); 2022 Apr; 12(5):. PubMed ID: 35629327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
    Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
    Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.